Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Analytik Jena Appoints New MD at Japanese Subsidiary

Published: Monday, December 09, 2013
Last Updated: Monday, December 09, 2013
Bookmark and Share
Dr. Marco Tilgner has been appointed new managing director of the Japanese subsidiary AJ Japan as of January 1, 2014.

Mr. Tilgner, who will report in his future role to Analytik Jena Chief Executive Officer Klaus Berka, already took over responsibility for finance and administration at the subsidiary two months ago as its CFO as part of comprehensive restructuring measures. 

"Marco Tilgner has international experience in the areas of finance and business management. He has also worked in Asia over many years and especially developed firm roots in Japan. His primary task will now be to implement the restructuring measures that are needed at our Japanese subsidiary in a consistent manner and to position AJ Japan effectively," said Klaus Berka.

The previous managing director, Yoshiharu Tada, who had led AJ Japan since its foundation in 2007 and built up the company successfully, will leave the company as planned at the end of the calendar year when he retires. Berka thanked Tada for his tireless dedication in building the subsidiary. Analytik Jena is represented in Japan with its two core business units, Analytical Instrumentation and Life Science. In the past business year, total revenue of approximately EUR 5.5 m was generated here. AJ Japan was, however, not able to meet the expectations of the parent company as part of changed regulatory conditions for measuring radioactive cesium with X-ray fluorescence devices, that were included as sales product into the portfolio after the Fukushima catastrophe.

In reaction to the overall negative developments, Analytik Jena had already begun a comprehensive program of reorganization and cost reduction before the end of the past financial year. The focus now lies on structures concentrating on cost and revenue as well as new sales initiatives in addition to the changes that have been made to the management. Analytik Jena expects its Japanese subsidiary to reach operative break even in the fourth quarter of the current 2013/2014 financial year once these measures have been implemented.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Analytik Jena AG Completes Merger of CyBio AG
Merger became effective upon entry into the commercial register of Analytik Jena AG.
Thursday, July 10, 2014
Analytik Jena CEO Klaus Berka Becomes an Advisor of the Fraunhofer IZI
Klaus Berka to advise the institute's management and the Executive Board of the Fraunhofer Gesellschaft.
Saturday, May 17, 2014
Analytik Jena Establishes Subsidiary in Thailand
New company to bolster Analytik Jena’s activities in the Southeast Asian market.
Tuesday, May 07, 2013
Analytik Jena to Develop Products for Sepsis Diagnostics
Cooperation to continue with the scientific centers for sepsis research in Jena.
Tuesday, May 07, 2013
Analytik Jena to Develop Products for Sepsis Diagnostics
Integration of a core team of former employees in the Life Science business unit. Cooperation to continue with the scientific centers for sepsis research in Jena.
Tuesday, May 07, 2013
Analytik Jena Increases Stake in its Subsidiary AJ Roboscreen to 100%
The Jena-based manufacturer of analytical instrumentation technology, life science instruments and optoelectronics has thus integrated another subsidiary further into the Group.
Monday, April 23, 2012
Scientific News
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!